# Kingdon Capital

> Kingdon Capital is a VC fund backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 11
- Last investment: Oct 2023
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.kingdon.com

Kingdon Capital is a VC fund in New York focused on Biotechnology and Health Care. Kingdon Capital Management, L.L.C. is an employee owned hedge fund sponsor. The firm provides its services to high net worth individuals and institutional clients. It invests in the public equity, fixed income, and alternative investment markets across the globe. The firm invests in growth and value stocks of all-cap companies. It also invests incurrency futures and options and long/short strategies to hedge its client's risks. It employs a top-down approach to select the economies and fundamental and technical analysis with a bottom-up stock picking approach to make investments. The firm conducts in-house research to make its investments. Kingdon Capital Management was founded in 1983 and is based in New York City.

## Contacts

5 contacts available for Kingdon Capital. Shizune tracks 1 team members at Kingdon Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kingdon-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 73% |
| Health Care | 5 | 45% |
| Medical | 4 | 36% |
| Life Science | 3 | 27% |
| Therapeutics | 3 | 27% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 3 | 27% |
| Series B | 2 | 18% |
| Series C | 2 | 18% |
| Series A | 1 | 9% |
| Series D | 1 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 73% |
| Israel | 1 | 9% |
| Latvia | 1 | 9% |
| Switzerland | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mark E. Kingdon | President, CEO/Managing Member & Founder | 0 | https://shizune.co/investors/profile/mark-e-kingdon |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hancock Jaffe Laboratories | Hancock Jaffe Laboratories develops life-enhancing bioprosthetic devices and technologies intended to achieve unparalleled outcomes for patients with debilitating cardiovascular diseases. Each device is designed to allow vascular and cardiothoracic surgeons to achieve maximum effectiveness while greatly reducing the time and complexity of currentprocedures in concert with a commitment to efficient health care delivery.Founded in 1987 by Norman Jaffe, Hancock Jaffe Laboratories is headquartered in Irvine, California. | $28M | Post-IPO Equity | Oct 06, 2023 |  |
| Sapience Therapeutics | Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $41M | Series B | May 31, 2022 |  |
| Shoreline Biosciences | Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $140M | Series B | Nov 02, 2021 |  |
| Jasper Therapeutics | Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $100M | Post-IPO Equity | Sep 27, 2021 |  |
| CeQur | CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.CeQur is developing the CeQurâ„¢ Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensiveinsulin therapy but want flexibility and freedom from multiple daily injections.CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group. The company is headquartered in Montreux, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts. | $115M | Series C | Apr 13, 2021 |  |
| Imago BioSciences | Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financialcommitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives. | $80M | Series C | Nov 19, 2020 |  |
| Stealth BioTherapeutics | Stealth is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. | $100M | Convertible Note | Jun 18, 2018 |  |
| SteadyMed Therapeutics | SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of thedevice will be tailored in accordance with the requirements of the company's partners. | $30M | Post-IPO Equity | Apr 23, 2017 |  |
| Mformation Technologies | Mformation Technologies, Inc. provides mobile device management software that is used by the mobile operators and service providers. It offers MFORMATION SERVICE MANAGER Suite, which is an integrated mobile device management software solution. The MFORMATION SERVICE MANAGER provides solutions for open mobile alliance DM-based provisioning andconfiguration; firmware over the air management; smart phone application management; diagnostics and repair for mobile devices; security management for mobile devices and data; enterprise device management; and customer experience management with voice and data services. The company was founded in 1999 and is headquartered in Edison, New Jersey with additional offices in Windsor, the United Kingdom; Bangalore, India; Beijing, the People’s Republic of China; Tokyo, Japan; Belfast, Northern Ireland; and Kuala Lumpur, Malaysia. | $20M | Series E | May 25, 2007 |  |
| Bill Me Later | Bill Me Later, Inc. provides payment and marketing technology solutions to multichannel retailers. It offers PayCapture, a set of credit tools; and Bill Me Later that enables customers to pay for purchases without providing credit card information. The company supports and delivers a suite of Web-engineered payment solutions; and offers consultingservices in the areas of payments, risk management, marketing, and technology. Bill Me Later, Inc. was formerly known as I4 Commerce, Inc. and changed its name to Bill Me Later, Inc. in August, 2007. The company was founded in 2000 and is based in Timonium, Maryland. As of November 7, 2008, Bill Me Later, Inc. operates as a subsidiary of eBay Inc. | $27.4M | Series A | Mar 01, 2006 |  |

10 of 11 investments shown.

## Co-investors
- [Federated Kaufmann Fund](https://shizune.co/investors/profile/federated-kaufmann-fund-2) — VC Fund, 2 deals together
- [Irving Investors](https://shizune.co/investors/profile/irving-investors) — VC Fund, 2 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 2 deals together
- [Velan Capital](https://shizune.co/investors/profile/velan-capital) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Kingdon Capital invest in?

Kingdon Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Kingdon Capital?

Public channels for Kingdon Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Kingdon Capital?

The team at Kingdon Capital includes Mark E. Kingdon (President, CEO/Managing Member & Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co